Bitcoin Depot Reports First Quarter 2024 Financial Results
May 14, 2024 08:05 ET
|
Bitcoin Depot Inc.
Strengthens Footprint with Over 2,000 New Retail Locations Signed in the First Quarter of 2024 Committed to Acquire Approximately 3,200 Additional Kiosks Year-to-Date to Support Expansion Strategy ...
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 08:05 ET
|
Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 14, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Franklin Electric Appoints Joe Ruzynski as CEO; Gregg Sengstack Remains Executive Chairperson
May 14, 2024 08:00 ET
|
Franklin Electric Co., Inc.
FORT WAYNE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Franklin Electric Co., Inc. (NASDAQ: FELE), a global leader in water and energy systems, announced today that its Board of Directors has appointed...
Ocugen Provides Business Update with First Quarter 2024 Financial Results
May 14, 2024 08:00 ET
|
Ocugen
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market...
Middlefield Banc Corp. Announces 2024 Second-Quarter Cash Dividend Payment
May 14, 2024 08:00 ET
|
Middlefield Banc Corp.
MIDDLEFIELD, Ohio, May 14, 2024 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per common share....
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
May 14, 2024 08:00 ET
|
Ovid Therapeutics Inc.
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1,...
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 14, 2024 08:00 ET
|
Reviva Pharmaceuticals
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia – – Registrational RECOVER-2 trial...
Plug Receives $1.66 Billion Conditional Commitment Loan Guarantee From Department of Energy for Green Hydrogen Development Pipeline
May 14, 2024 08:00 ET
|
Plug Power, Inc.
LATHAM, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, received a conditional commitment...
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
May 14, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for...